The presence of BRAF mutation in colorectal cancer is by itself a negative prognostic factor, as therapeutic strategies utilizing medications aimed at BRAF-V600E in CRC have shown comparatively lesser efficacy than, for example, in BRAF mutant melanoma. Here, BRAF is linked to colorectal cancer.